Stock Events

Stock Events

Aethlon Medical 

0
97
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

19AugExpected
Q2 2025
Q3 2025
Q4 2025
Q2 2026
-7.35
-5.13
-2.9
-0.68
Expected EPS
-0.6800141000000001
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-6.11MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Cytodyn
CYDY
Mkt Cap315.04M
CytoDyn Inc. focuses on innovative treatments for HIV and cancer, similar to Aethlon's focus on life-threatening diseases, making them direct competitors in the biotech space.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops drugs for life-threatening illnesses, including viral diseases, which competes with Aethlon's Hemopurifier therapy.
Sorrento Therapeutics
SRNE
Mkt Cap385,896
Sorrento Therapeutics, Inc. works on developing therapies for cancer, autoimmune, and infectious diseases, directly competing with Aethlon's disease treatment technologies.
Novavax
NVAX
Mkt Cap1.69B
Novavax, Inc. is involved in the development of vaccines for infectious diseases, competing with Aethlon's focus on therapeutic devices for viral diseases.
Moderna
MRNA
Mkt Cap58.11B
Moderna, Inc. specializes in drug discovery and drug development based on messenger RNA, competing in the infectious disease space with Aethlon.
Inovio Pharmaceuticals
INO
Mkt Cap147.86M
Inovio Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of DNA-based immunotherapies, competing with Aethlon's therapeutic technologies.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics AG specializes in gene editing technologies, which could compete with Aethlon's therapeutic approaches in treating diseases at the genetic level.
Novartis
NVS
Mkt Cap304.1B
Novartis AG is a global healthcare company that researches, develops, manufactures, and markets healthcare products, competing across a broad range of therapeutic areas including those targeted by Aethlon.

About

Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Show more...
CEO
ISIN
US00808Y6041
WKN
000A41NJ5

Listings

MU
DE
EJU.MU
STU
DE
EJU.STU
STU
DE
EJUN.STU
BOATS
BOATS
AEMD.BOATS

0 Comments

Share your thoughts

FAQ

What is Aethlon Medical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Aethlon Medical stocks are traded under the ticker EJU1.F.
What is Aethlon Medical revenue for the last year?▼
Aethlon Medical revenue for the last year amounts to 0 EUR.
What is Aethlon Medical net income for the last year?▼
EJU1.F net income for the last year is -6.11M EUR.
In which sector is Aethlon Medical located?▼
Aethlon Medical operates in the Other sector.
When did Aethlon Medical complete a stock split?▼
The last stock split for Aethlon Medical was on October 20, 2025 with a ratio of 1:10.